Picture of Angle logo

AGL Angle News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

RCS - Angle PLC - Parsortix outperforms other CTC systems in RCC

For best results when printing this announcement, please click on link below:
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20200227:nRSa2737Ea

RNS Number : 2737E  Angle PLC  27 February 2020

 

 For immediate release  27 February 2020

 

ANGLE plc ("the Company")

 

PARSORTIX OUTPERFORMS OTHER CTC SYSTEMS IN RENAL CELL CARCINOMA

 

Publication in International Journal of Molecular Sciences demonstrates
benefits of Parsortix "unbiased" CTC enrichment process

 

Workflow combines Parsortix with downstream process for single cell analysis
of each individual cancer cell

 

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is
pleased to announce that Istituto Nazionale Tumori di Milano, Milano, Italy
has published results of work, which assessed the performance of Parsortix(®)
in renal cell carcinoma (RCC) demonstrating key advantages of the Parsortix
system.

 

The disease is often asymptomatic (few or no symptoms) and about 30% of
patients with RCC present with metastatic disease.  Their prognosis is poor
with an overall 5-year survival rate of less than 20%.  A number of targeted
therapies have recently become available and a liquid biopsy to determine
whether such treatments might benefit individual patients would be highly
valuable.

 

Legacy circulating tumor cell (CTC) antibody-based systems have been
ineffective in RCC due to low expression of epithelial markers on the CTCs.
Istituto Nazionale Tumori di Milano compared the performance of a
Parsortix-based approach with a leading alternative CTC system.  The
Parsortix system was combined with a single cell picking system so that
individual CTCs could for the first time, in this tumor type, be harvested and
then analysed to assess the heterogeneity of the CTCs.

 

The Parsortix system greatly out-performed the alternative approach and, being
a marker-independent approach for CTC enrichment, it was described in the
publication as being "instrumental for increasing CTC detection and for being
able to separately identify the sub-populations by immunostaining".

 

The pilot study suggested that even the presence of a single CTC in a blood
sample prior to treatment may predict a reduced progression free survival.

 

The research has been published as a peer-reviewed publication in the
International Journal of Molecular Sciences and may be accessed via
https://angleplc.com/library/publications/
(https://angleplc.com/library/publications/) .

 

 

Dr  Vera Cappelletti, Group Leader, Istituto Nazionale Tumori di Milano,
Milano, Italy, commented:

"There is a major unmet clinical need in renal cell carcinoma for personalised
treatment decisions.  We hope that this original work will pave the way for
further investigation of how Parsortix can be used to benefit patients with
tumor types characterised by low expression of epithelial markers, such as
renal cell cancer."

 

ANGLE Founder and Chief Executive, Andrew Newland, commented:

"This publication adds to the body of evidence demonstrating the strong
advantages of the Parsortix system identifying new potential uses of the
system to improve the care of cancer patients."

 

As previously announced, following a Q-Submission meeting in January with the
US Food and Drug Administration (FDA), ANGLE is now progressing a full De Novo
FDA Submission with the prospect of FDA clearance in Q3 CY20, albeit the
outcome and timing of the FDA regulatory decision is entirely dependent on the
FDA's review and response to the Company's submission.

 

 

For further information ANGLE:

 

 ANGLE plc                                                        +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 finnCap Ltd (NOMAD and Joint Broker)                             +44 (0)20 7220 0500

 Corporate Finance - Carl Holmes, Simon Hicks, Max Bullen-Smith

 ECM - Alice Lane, Sunila de Silva

 WG Partners (Joint Broker)                                       +44 (0) 203 705 9330

 Nigel Barnes, Nigel Birks, Andrew Craig, Chris Lee

 FTI Consulting

 Simon Conway, Ciara Martin                                       +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                                         +1 (212) 850 5624

 

 

For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
(http://www.angleplc.com/the-parsortix-system/glossary/)

 

 

Notes for editors

 

About ANGLE plc www.angleplc.com (http://www.angleplc.com/)

 

ANGLE is a world leading liquid biopsy company with sample-to-answer
solutions. ANGLE's proven patent protected platforms include a circulating
tumor cell (CTC) harvesting technology and a downstream analysis system for
cost effective, highly multiplexed analysis of nucleic acids and proteins.

 

ANGLE's cell separation technology is called the Parsortix(®) system, and it
enables a liquid biopsy (a simple blood test) to be used to provide the cells
of interest to the user in a format suitable for multiple types of downstream
analyses. The system is based on a microfluidic device that captures cells
based on a combination of their size and compressibility.  The system is
epitope independent and can capture all types of CTCs as well as CTC clusters
in a viable form (alive).  CTCs enable the complete picture of a cancer to be
seen as being a complete cell they allow DNA, RNA and protein analysis and the
live cells harvested can be cultured.  The Parsortix technology is the
subject of 24 granted patents in Europe, the United States, China, Australia,
Canada, India, Japan and Mexico with three extensive families of patents are
being progressed worldwide.  The Parsortix system has a CE Mark in Europe for
the indicated use and FDA clearance is in process for the United States with a
400 subject clinical study and associated analytical studies in metastatic
breast cancer. ANGLE is seeking to be the first ever FDA cleared CTC
harvesting system and only the third ever FDA cleared liquid biopsy test.
ANGLE has already undertaken two separate 200 subject clinical studies under a
program designed to develop an ovarian cancer pelvic mass triage test, with
the results showing best in class accuracy (ROC-AUC) of 95.1%.  The pelvic
mass triage assay has undergone further refinement and optimisation, and is
currently in the process of a 200 patient clinical verification study.

 

ANGLE's technology for the multiplex evaluation of proteins and nucleic acids
of all types is called the HyCEAD(TM) Ziplex(®) platform and is based on a
patented flow through array technology.  It provides for low cost, highly
multiplexed, rapid and sensitive capture of targets from a wide variety of
sample types. A proprietary chemistry approach (the HyCEAD method) allows for
the capture and amplification of over 100 biomarkers simultaneously in a
single reaction. The HyCEAD Ziplex system is extremely sensitive and is ideal
for measuring gene expression and other markers directly from Parsortix
harvests and was used in the ovarian cancer pelvic mass triage test to achieve
best in class accuracy (ROC-AUC) of 95.1%.

 

ANGLE's proprietary technologies can be combined to provide automated,
sample-to-answer results in both centralised laboratory and point-of-use
cartridge formats.

 

ANGLE has established formal collaborations with world-class cancer centres
and major corporates such as Abbott, Philips and QIAGEN, and works closely
with leading CTC translational research customers.  These Key Opinion Leaders
(KOLs) are working to identify applications with medical utility (clear
benefit to patients), and to secure clinical data that demonstrates that
utility in patient studies.  The body of evidence as to the benefits of the
Parsortix system is growing rapidly from our own clinical studies in
metastatic breast cancer and ovarian cancer and also from KOLs with 29
peer-reviewed publications and numerous publicly available posters, available
on our website.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.   END  NRALQLLLBLLFBBK

Recent news on Angle

See all news